Document:

<PAGE>
                                                                   EXHIBIT 4.19

                         [DRAXIS LOGO]                        DR. MARTIN BARKIN
                                                              President and CEO
                                                 Telephone: (905) 677-0898 #236
                                                      FACSIMILE: (905) 677-5494
                                                       CELLULAR: (416) 726-8822
                                                             mbarkin@draxis.com

                                                                 April 15, 1999

                                                        PERSONAL & CONFIDENTIAL

DELIVERED

Roger Mailhot, Ph.D.
59 Byron Street
Oakville, Ontario
L6J 6E6

Dear Dr. Mailhot:

     Since August 13, 1990, the date you executed your original employment
agreement (the "Original Agreement"), Draxis Health Inc. ("Draxis") has
developed and expanded. Commensurate with the corporate growth, your duties
and responsibilities have increased and expanded. In addition, there have
been modifications to the terms of the Original Agreement. Accordingly, both
parties agree that it is beneficial to formally confirm the terms and
conditions of your employment with Draxis.

1.  EMPLOYMENT

     You shall be employed with Draxis as its Vice-President, Scientific and
Regulatory Affairs on the terms and conditions contained in this Agreement.
You shall report to the Chief Executive Officer of Draxis. Without limiting
the scope of your duties and responsibilities, as Vice-President, Scientific
and Regulatory Affairs, you shall be responsible for overseeing the
scientific and regulatory affairs of Draxis including, without limitation,
the clinical research of Draxis and the quality control of the products
produced by Draxis. In addition, you will perform any additional employment
responsibilities assigned to you by the President and Chief Executive Officer
of Draxis from time to time.

2.  PLACE OF EMPLOYMENT

     As Vice-President, Scientific and Regulatory Affairs, you will operate
from the Draxis offices located in Mississauga. It is acknowledged, however,
that there will be some domestic and international travel required. Such
travel is understood to be necessary in order to promote the business of
Draxis and so that you may remain at the forefront of scientific knowledge by
attending relevant scientific conferences or symposiums.

    DRAXIS HEALTH INC., 6870 Goreway Drive, Mississauga, Ontario L4V 1P1
                 Tel: (905) 677-5500 Fax: (905) 677-5502

    SANTE DRAXIS INC., 16751 Trans Canada Highway, Kirkland, Quebec H9H 4J4
                 Tel: (514) 694-8220 Fax: (514) 694-8201

<PAGE>

                                      -2-

Dr. Roger Mailhot                                               April 15, 1999

3.  RESEARCH

     Draxis recognizes that you are an acknowledged leader in the scientific
community in the field of Pharmacology. It is the intent of Draxis that as
its Vice-President, Scientific and Regulatory Affairs you will retain and
expand upon your extensive scientific knowledge. To this end, Draxis will
reimburse you for all professional fees or dues which you incur as a cost of
membership in those scientific Societies or Associations to which you belong.
In addition, subject to the confidentiality provisions discussed below,
Draxis will reimburse you for the costs of attendance at those conferences
where you present papers or other scientific research as a representative of
Draxis, or where you attend conferences necessary in order to retain your
expertise and scientific knowledge.

4.  BASE SALARY

     Draxis will pay to you during the term of this Agreement a gross salary
of $170,000 per annum, payable semi-monthly, in arrears, in 24 equal
installments of $7,083.33 ("Base Salary"). Such salary shall be subject to
annual review in accordance with Draxis' regular administrative practices of
salary review applicable to the executive employees of Draxis. Any salary
increases shall be determined on merit by the Chief Executive Officer of
Draxis. The Chief Executive Officer will advise you of any changes to your
salary in advance of the implementation date.

     As an officer of the company, Draxis will provide and pay for directors'
and officers' liability insurance and in any event will indemnify and save
you harmless from any action arising from your work for Draxis and its
affiliates (as such term is defined in the CANADA BUSINESS CORPORATIONS ACT)
("Affiliates").

5.  BENEFITS

     You will be entitled to participate in all benefit plans which Draxis
shall from time to time make available to its executive employees, subject to
applicable eligibility rules thereof. The benefits currently offered are:

     - major medical

     - dental

     - group life

     - long term disability

     - accidental death and dismemberment

6.  STOCK OPTION PLAN

     You will be eligible to participate in the Stock Option Plan of Draxis,
in accordance with the terms and conditions of that plan. As at the date
hereof, the following grants of stock options to you remain outstanding and
may be exercised by you in accordance with the terms and conditions pursuant
to which each grant was made and the terms of this Agreement:

<TABLE>
<CAPTION>
      NO. OF OPTIONS               PRICE         EXPIRY DATE
      --------------               -----         -----------
      <S>                          <C>           <C>
         30,000                    $3.05         August 11, 2003
</TABLE>
<PAGE>
                                      -3-

Dr. Roger Mailhot                                               April 15, 1999

7.  STOCK OWNERSHIP PLAN

     You will be eligible to participate in the Stock Ownership Plan which
Draxis shall from time to time make available to employees, subject to
applicable eligibility rules thereof and in accordance with the terms and
conditions of that plan.

8.  EMPLOYEE PARTICIPATION SHARE PURCHASE PLAN

     You will be eligible to participate in the Draxis Employee Participation
Share Purchase Plan which Draxis shall from time to time make available to
its employees, subject to applicable eligibility rules thereof and in
accordance with the terms and conditions of that plan. As at the date hereof,
you have been granted 50,000 Employee Participation Shares, Series A and
100,000 Employee Participation Shares, Series B.

9.  DISCRETIONARY BONUS

     The Chief Executive Officer and the Compensation Committee, in their
sole discretion, may declare a bonus payable. Such bonus payment is not
guaranteed and payment of a discretionary bonus in any prior year is not a
promise or guarantee of payment in subsequent years. Further, to receive any
discretionary bonus payment, should one be declared, you must be employed on
December 31 of the calendar year for which the bonus is declared. Should a
discretionary bonus be declared, you may be eligible to receive an amount up
to a maximum equivalent to 40% of your Base Salary, as determined by the
Chief Executive Officer of Draxis and the Compensation Committee of the Board
of Directors in their sole discretion.

10.  VACATION

     Each calendar year, commencing on January 1, you shall be entitled to
four weeks vacation per annum to be taken at a time or times acceptable to
Draxis, having regard to its operations. There shall be no vacation time
carried over from one calendar year into the following calendar year, unless
previous authorization has been received from the Chief Executive Officer of
Draxis.

11.  EXPENSES

     Draxis agrees that it shall reimburse you for all authorized travelling
and other out of pocket expenses actually and properly incurred in connection
with your duties with Draxis and its Affiliates (the "Company"). For all such
expenses you agree you will furnish statements and vouchers as and when
required by Draxis.

12.  DEDUCTIONS

     All salary and other payments and allowances outlined in this Agreement
are subject to such withholding and deduction at source as may be required by
law.

13.  EMPLOYEE'S COVENANTS

     You agree that you shall devote the whole of your working time,
attention and ability to the business of Draxis and shall use reasonable best
efforts to promote the interests of Draxis.

<PAGE>

                                      -4-

Dr. Roger Mailhot                                               April 15, 1999

     Further, you agree that you shall duly and diligently perform all the
duties assigned to you while in our employ and shall well and faithfully
serve Draxis. You agree that while employed with Draxis that you shall not,
without the prior written consent of Draxis which consent shall not be
unreasonably withheld, engage or otherwise be concerned in any other business
or occupation, or become a director, officer, agent or employee of any other
entity.

14.  CONFIDENTIAL INFORMATION, NON-SOLICITATION AND NON-COMPETITION

(a)  NON-DISCLOSURE OF CONFIDENTIAL INFORMATION

     As Vice-President, Scientific and Regulatory Affairs, you acknowledge
that you are creating, having access to, and require knowledge of
confidential and commercially valuable information of the Company, the
unauthorized use or disclosure of which could cause the Company serious and
irreparable damage.

     (1) "Confidential Information" means all information, and all documents
and other tangible things recording any such information, relating to or
useful in connection with the business of the Company, whether or not a
trade secret within the meaning of the applicable law, which at the time or
times concerned is not generally known to Competitors (as defined below) and
which has been or is from time to time disclosed to or developed by you as a
result of your employment with Draxis. Confidential Information includes, but
is not limited to, the following information of the Company:

         (i)     new products;

         (ii)    marketing strategies and plans;

         (iii)   development strategies and plans;

         (iv)    manufacturing processes and technologies;

         (v)     research in progress and unpublished manuals or know how;

         (vi)    regulatory filings;

         (vii)   identity of and relationship with licensees, licensors or
                 suppliers;

         (viii)  finances, financial information, financial management
                 systems;

         (ix)    market research;

         (x)     market experience with products;

         (xi)    customer lists;

         (xii)   compensation and benefits paid to employees; and

         (xiii)  any other research, information or documents which you are
                 told or reasonably ought to know that the Company regards
                 as proprietary or confidential.

     (2) You agree that you should hold all Confidential Information in the
strictest confidence, as a fiduciary. Without limiting such obligation, you
shall use Confidential Information only at times and places designated by the
Company in furtherance of the business of the Company. You shall not, except
where the Company otherwise provides its prior written consent, or where
required by law, directly or indirectly disclose to any Person any
Confidential Information, directly or indirectly sell, give, loan or
otherwise transfer any Confidential Information or copy thereof to any
Person, publish, lecture on or display any Confidential Information to any
Person or use Confidential Information for your own benefit or the benefit of
any other Person.
<PAGE>

                                    - 5 -
Dr. Roger Mailhot                                                April 15, 1999

      (3)     Your obligations under this Section shall remain in effect with
respect to each item of Confidential Information until the date upon which
such Confidential Information has been publicly disclosed in a manner
properly authorized by the Company or otherwise has become known to
Competitors without any breach of this Section by you.

      (4)     For purposes of this Agreement, "Competitor" shall mean any
Person which engages or is preparing to engage, in whole or in part, in the
design, development, manufacture, marketing or sale of any products or
services which compete directly with a product or service which, during the
period of your employment, the Company marketed or at the time of termination
of this Agreement and your employment hereunder, is then preparing to market.

      (5)     For purpose of this Agreement, "Person" shall include
individuals, partnerships, associations, trusts, unincorporated organizations
and corporations.

(b)   NON-SOLICITATION AND NON-COMPETITION
      (1)     You acknowledge that the pharmaceutical and over-the-counter
drug industries are highly competitive businesses.  You are a key executive
of Draxis, and as a result of your senior position, you confirm that you have
acquired extensive background in and knowledge of the Company's business and
the pharmaceutical and over-the-counter drug industries in which the Company
operates.  You further acknowledge that the Company develops and markets its
products on a North American basis.  Accordingly, you agree that in the
course of your employment with Draxis and thereafter for a period of one year
(or if such period is held to be excessive by a court of competent
jurisdiction then for a period of six months) you shall not, without the
prior written authorization of the Chairman of the Board of Directors whether
as principal, as agent, or as an employee of, or in partnership, or
association with any other Person, in any manner whatsoever directly or
indirectly:

      (i)     become employed by or associated or affiliated with any
              Competitor of the Company in North America in a function
              dealing with a product or service which, during the
              twelve-month period immediately prior to the termination of this
              Agreement and your employment hereunder, for any reason,
              competed directly with a product or service of the Company;

      (ii)    seek to employ or encourage others to employ or otherwise
              engage employees, agents or subcontractors of the Company (who
              are employees, agents or subcontractors on the date this
              Agreement terminated) or seek to in any way disrupt their
              business relationship with the Company;

      (iii)   obtain by any means whatsoever the business of any Person who
              at the time of the termination of this Agreement and your
              employment hereunder, was a customer of the Company, if to obtain
              such business may result in a reduction of that Person's business
              with the Company;

      (iv)    approach any Person who at the time of the termination of this
              Agreement and your employment hereunder was a customer of the
              Company with the intention of soliciting or enticing the
              business of that Person away from the Company.

(c)   INVENTIONS AND PATENTS
      In the event that you contribute to any patentable invention arising
out of or in the course of your employment with Draxis, any such patentable
invention shall be the exclusive property of Draxis or its Affiliate (as
appropriate) and Draxis or its Affiliate (as appropriate) shall have the
exclusive right to file patent applications in its name in connection
therewith.  You agree that you will co-operate with the Company and provide
all necessary assistance in the filing and prosecution, if necessary, of such
patent applications.

<PAGE>

                                    - 6 -
Dr. Roger Mailhot                                                April 15, 1999

(d)   COPYRIGHT

      You acknowledge and agree that all work created by you in the course of
your employment, and all copyrights and similar rights in all such works,
shall from the inception of the creation, be the exclusive and absolute
property of Draxis or its Affiliate (as appropriate).  If for any reason any
of such rights are invested in you, then you will hereby assign those rights
to Draxis or its Affiliate (as appropriate) exclusively and absolutely.  You
further waive all moral rights in such works for the benefit of Draxis or its
Affiliate (as appropriate) and their respective successors, licensees and
assigns.

(e)   REASONABLENESS

      You agree that the obligations set out in Sections 14(a) and (b),
together with your other obligations under this Agreement, are reasonably
necessary for the protection of the Company's proprietary and business
interests and you expressly agree that:

      (i)     the scope of each of the covenants set out in paragraphs 14(a)
              and (b) above are in all respects, and in particular, in respect
              of area, time and subject matter, necessary and reasonable
              because the Company is marketing its products on a North American
              basis;

      (ii)    given your general knowledge and experience, the obligations
              contained in this Agreement will not preclude you from becoming
              gainfully employed with other employers who are not Competitors
              following termination of this Agreement and your employment
              hereunder for any reason;

      (iii)   your agreement to Sections 14(a) and (b) is a key incentive to
              Draxis formalizing the current terms and conditions of your
              employment.

(f)   BREACH OF AGREEMENT

      You also recognize that any breach of the terms and conditions of this
Agreement by you will result in material damage to the Company, although it
may be difficult for Draxis to establish the monetary value of such damage.
You therefore agree that Draxis shall be entitled to injunctive relief, in
addition to any other remedies available to it, in a court of appropriate
jurisdiction in the event of any breach or threatened breach by you of any of
the provisions of this Agreement.

15.   TERMINATION OF EMPLOYMENT

(a)   TERMINATION BY DRAXIS FOR CAUSE

      Draxis may terminate this Agreement and your employment hereunder at
any time for cause without payment of any kind of compensation either by way
of anticipated earnings or damages of any kind.

(b)   TERMINATION BY DRAXIS WITHOUT CAUSE BUT WITH NOTICE

      Draxis may terminate this Agreement and your termination hereunder by
providing to you two years' actual notice of termination.  At its sole
discretion, Draxis may provide to you a shorter period of notice of
termination, in which case, the payments referred to in 15(c) shall be
applicable, but such payments as may be required by sections 15(c)(1) and (4)
shall be reduced by the notice provided, so that the total notice and
compensation in lieu of notice provided to you shall be equivalent to two
years from the date you are advised of the termination.

(c)   TERMINATION BY DRAXIS WITHOUT CAUSE AND WITHOUT NOTICE

      Draxis may terminate this Agreement and your employment hereunder, in
its sole discretion, without notice and without cause, effective immediately
upon the date you are advised of the termination.

<PAGE>

                                      - 7 -
Dr. Rogert Mailhot                                               April 15, 1999

      Except as outline in section 15(b), if your employment is terminated
without cause pursuant to this section, Draxis shall:

              (1)       Pay to you a severance allowance equivalent to two
                        years' of your then Base Salary in a lump sum within
                        two weeks following the date of such termination.

              (2)       Pay to you all outstanding vacation pay and any
                        earned but unpaid salary up to the date of such
                        termination within two weeks of the date of
                        termination.

              (3)       Reimburse you for any business expenses incurred by
                        you up to and including the date of such termination
                        following provision by you of applicable receipts.

              (4)       Permit you to retain all stock options, Employee
                        Participation Shares and other securities which have
                        vested or accrued during your employment with Draxis
                        and which will accrue or vest during the two year
                        period following termination of this Agreement and
                        your employment hereunder, as if you had remained
                        employed for that two year period.

              (5)       Ensure that it has complied with all statutory
                        obligations imposed by the EMPLOYMENT STANDARDS ACT.

      The payment referred to in paragraph 1, above, shall be guaranteed and
shall not be subject to set off or deduction as a result of your obtaining
alternate employment following such termination or otherwise mitigating any
damages arising from such termination.  Further, the payment referred to in
paragraph 1, above, is inclusive of all statutory payments, including
statutory termination and severance, which may be owed to you.

      The amounts paid to you pursuant to this paragraph shall be subject to
all required deductions.

      Upon termination of your employment in accordance with this Section
15(c), you shall return to Draxis all stock options, Employee Participation
Shares and other securities which have not vested or accrued during your
employment with Draxis, and will not vest or accrue during the two year
period following termination of this Agreement.

(d)   TERMINATION PAYMENT FOLLOWING A CHANGE OF CONTROL

(1)   In accordance with paragraph 15(d)(2), below, if there is a Change of
Control (as hereinafter defined) you shall be entitled to the following:

              A.        the amounts of any unpaid salary earned up to and
                        including date of termination;

              B.        any unpaid vacation pay earned up to and including
                        date of termination;

              C.        a lump sum amount, equal to three times your then
                        current Base Salary in effect immediately prior to the
                        date of the Change of Control:

              D.        any additional statutory obligations imposed by the
                        EMPLOYMENT STANDARDS ACT.

              E.        the right to retain and exercise all stock options,
                        Employee Participation Shares and other securities
                        which have vested or accrued during your employment
                        with Draxis and which will accrue or vest during the
                        three year period immediately following the Change of
                        Control, as if you were employed by the successor
                        employer for that three year period.

<PAGE>

                                       - 8-
Dr. Roger Mailhot                                                April 15, 1999

      The payment referred to in paragraph 15(d)(1)(C), above, shall be
guaranteed and shall not be subject to set off or deduction as a result of
your obtaining alternate employment following termination or otherwise
mitigating any damages arising from termination.  Further, notwithstanding
paragraph 15(d)(1)(D) above, the payment referred to in 15(d)(1)(C) above is
inclusive of all statutory payments, including statutory termination and
severance, which may be owed to you following termination.

      The amounts paid to you pursuant to this paragraph shall be subject to
all required deductions.

      Upon termination of your employment in accordance with this Section
15(d), you shall return to Draxis all stock options, Employee Participation
Shares and other securities which have not vested or accrued during your
employment with Draxis, and will not vest or accrue during the three year
period following termination of this Agreement.

(2)   These payments outline in 15(d)(1) shall become due and payable if, and
only if:

           A.    there has been a Change of Control; and

           B.    within 24 months following any Change of Control:

                 (i)    your employment is terminated without cause by Draxis
                        or by any successor employer to Draxis, as the case may
                        be; or

                 (ii)   by its conduct as described below, Draxis or any
                        successor employer to Draxis, as the case may be,
                        constructively terminates your employment by:

                        -   relocating the position and/or location of your
                            principal office more than 20 kilometers from the
                            location of your office on the date immediately
                            prior to the Change of Control, without your
                            consent; or

                        -   materially reducing your title, reporting
                            relationship, responsibilities or authority
                            without your consent; or

                        -   reducing the salary paid to you by the successor
                            employer or terminating or materially reducing the
                            value of your benefit programs, including, but
                            not limited to , life insurance benefits,
                            accidental death and dismemberment benefits, long
                            term disability benefits, extended health
                            coverage, dental benefit, which are referred to in
                            paragraph 5 above; and

           C.    you elect in writing to receive the payments outlined in
                 Section 15(d)(1).

(3)   For purposes of this agreement "Change in Control" means a transaction
or series of transactions whereby directly or indirectly;

           A.    any Person or combination of Persons acting jointly and in
                 concert (other than you or a corporation controlled directly
                 or indirectly by you) acquires a sufficient number of
                 securities of Draxis to materially affect the control of
                 Draxis as defined below.  For the purposes of this Agreement,
                 a Person or combination of Persons acting jointly and in
                 concert, holding shares or other securities in excess of the
                 number which, directly or following the conversion or exercise
                 thereof, would entitled the holders thereof to cast 20% or
                 more of the votes attached to all shares of Draxis which may
                 be cast to elect directors of Draxis, shall be deemed

<PAGE>

                                      -9-

Dr. Roger Mailhot                                               April 15, 1999

              to affect materially the control of Draxis, in which case the
              Change in Control shall be deemed to occur on the date that is
              the later of the date that the security representing one more
              than that required to cast 20% of the votes attached to all
              shares of Draxis which may be cast to elect directors of Draxis
              is acquired or the date on which the persons acting jointly and
              in concert agree to so act;

          B.  Draxis shall consolidate or merge with or into, amalgamate with,
              or enter into a statutory arrangement or business combination
              with, any other Person (other than a corporation controlled
              directly or indirectly by you) and, in connection therewith, all
              or part of the outstanding shares of Draxis which have voting
              rights attached thereto shall be changed in any way,
              reclassified or converted into, exchanged or otherwise acquired
              for shares or other securities of Draxis or any other Person or
              for cash or any other property and control of Draxis is thereby
              materially affected, as defined above, in which case the Change
              in Control shall be deemed to occur on the date of closing of
              the consolidation, merger, amalgamation, statutory arrangement
              or business combination, as the case may be; or

          C.  Draxis shall sell or otherwise transfer, including by way of
              the grant of a leasehold interest (or one or more subsidiaries of
              Draxis shall sell or otherwise transfer, including without
              limitation by way of the grant of a leasehold interest) property
              or assets aggregating more than 50% of the consolidated assets
              (measured by either book value or fair market value based on the
              most recent audited financial statements) of Draxis and its
              subsidiaries as at the end of the most recently completed
              financial year to any other Person or Persons, in which case the
              Change of Control shall be deemed to occur on the date of
              transfer of the assets representing one dollar more than 50% of
              the consolidated assets;

          other than a transaction or series of transactions which involves a
          sale of securities or assets of Draxis with which you are involved
          as a purchaser in any manner, whether directly or indirectly, and
          whether by way of participation in a corporation or partnership
          that is a purchaser or by provision of debt, equity or purchase
          leaseback financing (but excluding where your sole involvement
          with such a purchase is the ownership of an equity interest of less
          than 5% of the acquirer where the acquirer is a public company) and
          you and persons acting jointly and in concert with you hold
          securities of the acquirer which, directly, or following the
          conversion or exercise thereof, would entitle the holders thereof
          to cast 5% or more of the votes attached to all shares or other
          interests of the acquirer which may be cast to elect directors or
          the management of the acquirer.

Draxis shall use its reasonable best efforts to require any successor
(whether direct or indirect) to all or substantially all of its shares and/or
assets to expressly agree in writing to assume and to perform this Agreement
in the same manner that Draxis would have been required to perform it if no
such succession had occurred. If Draxis fails to obtain any such successor's
express written agreement prior to the effective date of such succession,
such failure shall be deemed to be a termination of your employment by Draxis
and such termination shall be deemed to have occurred on the date immediately
prior to the Change of Control date. In such event, at the discretion of
Draxis, Section 15(b) or (c) will not be applicable, and Draxis shall pay to
you those amounts in section 15(d)(1) above and section 15(h) shall be
applicable.

<PAGE>

                                      -10-

Dr. Roger Mailhot                                               April 15, 1999

(e)  TERMINATION BY DRAXIS WITHOUT CAUSE UPON DISABILITY

     If, as a result of incapacity due to physical or mental illness, you are
unable to render services of substantially the kind and nature, and
substantially to the extent required to be rendered in accordance with this
Agreement, and if such incapacity is expected to continue for a period of at
least six consecutive months from the date such incapacity commenced
("Absence Date") this Agreement may be deemed to be frustrated. Your
employment hereunder shall cease effective on the tenth day after written
notice of cessation to you, provided that prior to such cessation Draxis has
been furnished with the written certification of a qualified medical doctor
designated by Draxis and you jointly which states that you are and are
expected to continue to be for at least six consecutive months from the
Absence Date, unable to render such services by reason of such incapacity and
the date upon which such incapacity commenced. If Draxis and you are unable
to agree on the designation of a qualified medical doctor to make such
determination, then each party shall designate a medical doctor who,
together, shall agree upon a third qualified medical doctor to make such
determination. The decision of the third medical doctor shall be binding on
Draxis and you. You consent to submit to such examination as may be required
by any such medical doctor or doctors.

     If your employment ceases pursuant to this section, you shall be
entitled to receive a total amount equivalent to two years of your then
current Base Salary, commencing the date upon which the notice of cessation
is delivered and payable in 48 regular payments on the regular Draxis pay
days. If you are in receipt of disability benefits payable pursuant to the
benefit plans described above, then each semi-monthly payment payable by
Draxis shall be reduced by an amount equivalent to the disability benefits
payment received during that pay period. Notwithstanding the cessation of
your employment pursuant to this section, you shall be entitled to retain and
exercise all stock options and Employee Participation Shares granted to you
during your employment with Draxis.

(f)  DEATH

     In the event that you should die during the term of this Agreement, your
employment shall automatically terminate. All salary, vacation pay and any
bonus payments earned to date of death but unpaid will be paid to your
estate, however, no other payment of any compensation either by way of
anticipated earnings or damages of any kind shall be paid.

(g)  RESIGNATION AND RETIREMENT

     You shall provide Draxis with three months' notice, in writing, of your
resignation or your retirement from Draxis.

(h)  NO FURTHER NOTICE OR COMPENSATION

     For further clarity, in the event of termination of this Agreement and
your employment hereunder for any reason, the terms provided in the event of
termination under the Draxis Stock Option Plan, Stock Purchase and Bonus
Plan, Stock Ownership Plan and Employee Participation Share Purchase Plan
shall apply.

16.  FAIR AND REASONABLE

     The parties confirm that the notice requirements and pay in lieu of
notice provisions set out above in section 15 are fair and reasonable and
that no further notice or payments of any kind are owed or required. The
parties agree that upon any termination of this Agreement by Draxis or upon
any termination of this Agreement by you, that you shall have no action,
cause of action, claim or demand, either statutory or at common law, against
Draxis or any other Person as a consequence of such termination.
<PAGE>

                                      -11-

Dr. Roger Mailhot                                               April 15, 1999

17.  RETURN OF PROPERTY

     In the event your employment with Draxis is terminated for any reason,
including resignation or retirement, you will immediately return all Draxis
property in your possession or under your control.

18.  PROVISIONS OPERATING FOLLOWING TERMINATION

     Notwithstanding any termination of your employment with or without
cause, sections 14, 15, 16 and 17, and any provision of this Agreement
necessary to give it efficacy, shall continue in full force and effect
following such termination.

19.  SEVERABILITY

     If any provision of this Agreement is determined to be invalid or
unenforceable, in whole or in part, such invalidity or unenforceability shall
attach only to such provision or part thereof and the remaining part of such
provision and all other provisions hereof shall continue in full force and
effect.

20.  NOTICE

     Any notice to be given in connection with this Agreement shall be given
in writing and may be given by personal delivery or by registered mail
addressed to the recipient as follows:

     To:  Dr. R. Mailhot
          59 Byron Street
          Oakville, Ontario
          L6J 6E6

     To:  Draxis Health Inc.
          6870 Goreway Drive
          Mississauga, Ontario
          L4V 1P1
          ATTENTION: PRESIDENT AND CHIEF EXECUTIVE OFFICER

or such other address or individual as may be designated by notice by either
party to the other. Any notice given by personal delivery shall be deemed to
have been given on the day of actual delivery and, if made or given by
registered mail on the third day, other than a Saturday, Sunday or a
statutory holiday in Ontario, following the deposit thereof in the mail.

21.  GOVERNING LAW

     This Agreement shall be governed by and construed in accordance with the
law of the Province of Ontario.

22.  BENEFIT OF AGREEMENT

     This Agreement shall enure to the benefit of and be binding upon your
heirs, executors, administrators and legal personal representatives and the
successors and assigns of Draxis respectively.

<PAGE>

                                      -12-

Dr. Roger Mailhot                                               April 15, 1999

23.  ENTIRE AGREEMENT

     This Agreement and the Draxis Code of Ethics constitute the entire
agreement between the parties with respect to your terms and conditions of
employment and cancel and supersede any prior understandings and agreements
between the parties to this Agreement including the letter dated August 13,
1990. There are no representations, warranties, forms, conditions,
undertakings or collateral agreements expressed, implied or statutory between
the parties other than as expressly set forth in this Agreement and the
Draxis Code of Ethics. You waive any right to assert a claim in tort based on
any pre-contractual representations, negligent, or otherwise, made by Draxis.

     To acknowledge that the terms of employment as expressed in this
Agreement are acceptable to you, please execute the enclosed copy of this
letter as indicated below and return it to me at your earliest opportunity.

                                 Yours truly,

                                 DRAXIS HEALTH INC.

                           Per:  /s/ Martin Barkin
                                 Martin Barkin, M.D., F.R.C.S.C.
                                 President and Chief Executive Officer

     I accept the above-noted terms of employment with Draxis as
Vice-President, Scientific and Regulatory Affairs and in consideration of my
continued employment with Draxis and the payment of $5.00, the sufficiency
and receipt of which is acknowledged, I agree to comply with and be bound by
the terms of employment outlined in this Agreement.

     Dated at Mississauga, the 25 day of June, 1999.

/s/ Olha Luszowski                        /s/ Roger Mailhot
-----------------------------------       --------------------------------------
Witness                                   Roger Mailhot, Ph.D.<PAGE>

                                                                   EXHIBIT 4.20

                              [DRAXIS LETTERHEAD]

                                                                 April 15, 1999
                                                        PERSONAL & CONFIDENTIAL
DELIVERED

Mr. Dan Brazier
316 Lori Avenue
Stouffville, Ontario
L4A 6C2

Dear Mr. Brazier:

     Since July 17, 1998, the date you executed your original employment
agreement (the "Original Agreement"), Draxis Health Inc. ("Draxis") has
restructured its marketing operations by amalgamating the management and
operations of Draxis' two Canadian pharmaceutical marketing units which
formerly operated separately as Draxis Pharmaceutica ("Draxis"), and
SpectroPharm Dermatology (the amalgamated Canadian pharmaceutical unit
hereinafter called "Draxis Pharmaceutica"). Commensurate with that
restructuring, your duties and responsibilities have increased and expanded.
In addition, there have been modifications of the Original Agreement.
Accordingly, both parties agree that it is beneficial to formally confirm the
terms and conditions of your employment with Draxis.

     With respect to Sections 13 and 14 of this Agreement, we acknowledge
that you have fully disclosed to us the nature and extent of your interest in
Carr Brazier Group Inc. and "Ultimate Essentials", and we specifically consent
to your continued interest and involvement therein.

1.   EMPLOYMENT

     You shall be employed with Draxis as its President, DRAXIS
Pharmaceutica, a division of Draxis Health Inc. on the terms and conditions
outlined in this Agreement. You shall report to the President and Chief
Executive Officer of Draxis or his designate. As President of Draxis
Pharmaceutica, you shall be responsible for all aspects of the business in
order to maximize its value to Draxis including exercising sound leadership,
management, human resources management, financial performance, marketing and
selling, new product development and/or in-licensing, and business
development. You will also participate as a member of the Draxis Corporate
Management group. In addition, you will perform any additional employment
responsibilities commensurate with your position as President, Draxis
Pharmaceutica which may be assigned to you by the President and Chief
Executive Officer of Draxis, or his designate, from time to time.

<PAGE>

                                     -2-

Dan Brazier                                                     April 15, 1999

2.   BASE SALARY

     Draxis will pay to you during the term of this Agreement a salary of
$165,000 per annum, payable semi-monthly, in arrears ("Base Salary"). Such
salary shall be subject to review in accordance with Draxis' regular
administrative practices of salary review applicable to members of the Draxis
Corporate Management group. Any salary increases shall be determined on merit
by the Chief Executive Officer and President of Draxis. The Chief Executive
Officer will advise you of any changes to your salary in advance of the
implementation date.

3.   BENEFITS

     You will be entitled to participate in all benefit plans which Draxis
shall from time to time make available to its executive employees, subject to
applicable eligibility rules thereof. The benefits currently offered are:

     - major medical
     - dental
     - group life
     - long term disability
     - accidental death and dismemberment

4.   STOCK OPTION PLAN

     You will be eligible to participate in Draxis' Stock Option Plan,
in accordance with the terms and conditions of that plan and as described in
this paragraph. Draxis has granted you options to purchase 100,000 shares.
These options shall vest as follows:

     (a) 33,334 options on the later of (i) the date upon which the Chief
         Executive Officer of Draxis confirms that the restructuring
         associated with the discontinuation of the detailing of
         SpectroDerm-Registered Trademark- to dermatologists in the United
         States, and the severance of Draxis employees associated therewith,
         has been successfully completed and (ii) July 31, 1999;

     (b) 33,333 options on the later of (i) 30 days following the end of the
         fiscal quarter when the Contribution of Draxis Pharmaceutica for the
         immediately preceding four fiscal quarters exceeds $2.1 million and
         (ii) July 31, 2000; and

     (c) 33,333 options on the later of (i) 30 days following the end of the
         fiscal quarter when the Contribution of Draxis Pharmaceutica for the
         immediately preceding four fiscal quarters exceeds $4.0 million and
         (ii) July 31, 2001.

     The price of each option shall be the closing price of the Draxis shares
on The Toronto Stock Exchange on the trading date immediately preceding the
date of the grant. The options may be exercised in whole or in part at any
time within five years after the date of the grant, subject to vesting as set
out above.

     For purposes of this Agreement:

     (a)   "Revenues" is defined as product sales less returns as determined
           on a consistent basis in accordance with Canadian generally
           accepted accounting principles.

<PAGE>

                                     -3-

Dan Brazier                                                     April 15, 1999

     (b)   "Contribution" is defined as Revenues less cost of sales and
           direct operating expenses as determined on a consistent basis in
           accordance with Canadian generally accepted accounting principles.
           Direct operating expenses shall not include: (a) corporate
           overheads or any other such allocations, (b) annual bonus accruals,
           or (c) research and development expenditures.

     For greater certainty, Revenues and Contribution shall not include
one-time or non-recurring items (e.g. milestone payments, asset write-downs,
etc.).

5.   STOCK OWNERSHIP PLAN

     You will be eligible to participate in the Stock Ownership Plan which
Draxis shall from time to time make available to employees, subject to
applicable eligibility rules thereof and in accordance with the terms and
conditions of that plan.

6.   EMPLOYEE PARTICIPATION SHARE PURCHASE PLAN

     You will be eligible to participate in the Employee Participation Share
Purchase Plan which Draxis shall from time to time make available to its
employees, subject to applicable eligibility rules thereof and in accordance
with the terms and conditions of that plan.

7.  DISCRETIONARY BONUS

     The President and Chief Executive Officer of Draxis, or his designate,
and the Draxis Compensation Committee, in their sole discretion, may declare
a bonus payable. Such bonus payment is not guaranteed and payment of a
discretionary bonus in any prior year is not a promise or guarantee of
payment in subsequent years. Further, to receive any discretionary bonus
payment, should one be declared, you must be employed on December 31 of the
calendar year for which the bonus is declared. Commencing January 1, 1999,
for that calendar year and each calendar year thereafter, should a
discretionary bonus be declared, you may be eligible to receive an amount up
to a maximum equivalent to 40% of your then Base Salary, as determined by the
President and Chief Executive Officer of Draxis, or his designate, and the
Draxis Compensation Committee in their sole discretion.

8.   SIGNING AND RETENTION BONUS

     As an incentive to encourage you to become employed with Draxis, and to
remain employed with Draxis, you were paid the gross amount of $20,000
("Retention Bonus"). You expressly agree to fully repay to Draxis the total
amount of $20,000 in the event that you resign, retire or are terminated with
cause prior to August 1, 2000.

     By executing this Agreement, in the event that you resign, retire or are
terminated for cause on or prior to August 1, 2000, you hereby authorize
Draxis to deduct $20,000 (or a portion thereof), from any outstanding amounts
which Draxis may owe to you at the time of your resignation, retirement or
termination for cause.

<PAGE>
                                   - 4 -

Dan Brazier                                                     April 15, 1999

9.  VACATION

    Each calendar year, commencing on January 1, 1999 you shall be entitled
to four weeks vacation per annum to be taken at a time or times acceptable to
Draxis, having regard to its operations. There shall be no vacation time
carried over from one calendar year into the following calendar year, unless
previous authorization has been received from the President and Chief
Executive Officer of Draxis, or his designate.

10. PROFESSIONAL FEES

    Draxis will reimburse you for reasonable legal fees incurred by you in
the negotiation of this Agreement.

11. EXPENSES

    Draxis agrees that it shall reimburse you for all authorized travelling
and other out of pocket expenses actually and properly incurred in connection
with your duties with Draxis. For all such expenses you agree you will
furnish statements and vouchers as and when required by Draxis. Mileage shall
be reimbursed in accordance with the prevailing Revenue Canada guideline.

12. DEDUCTIONS AND CURRENCY

    All salary and other payments and allowances outlined in this Agreement
are subject to such withholding and deduction at source as may be required by
law. All salary payments and allowances outlined in this Agreement shall be
payable in Canadian funds.

13. EMPLOYEE'S COVENANTS

    You agree that you shall devote the whole of your working time, attention
and ability to the business of Draxis and shall use your best efforts to
promote the interests of Draxis.

    Further, you agree that you shall duly and diligently perform all the
duties assigned to you while in our employ and shall well and faithfully
serve Draxis. You agree that while employed with Draxis you shall not,
without the prior written consent of the President and Chief Executive
Officer of Draxis, or his designate, engage or otherwise be concerned in any
other business or occupation, or become a director, officer, agent or
employee of any other entity.

14. CONFIDENTIAL INFORMATION, NON-SOLICITATION AND NON-COMPETITION

(a) NON-DISCLOSURE OF CONFIDENTIAL INFORMATION

    As President of Draxis Pharmaceutica, you acknowledge that you are
creating, having access to, and require knowledge of confidential and
commercially valuable information of Draxis Pharmaceutica and Draxis and its
Affiliates (as defined below), the unauthorized use or disclosure of which
could cause the Company (as defined below) serious and irreparable damage.

    (1) "Confidential Information" means all information, and all documents
and other intangible things recording any such information, relating to or
useful in connection with the business of Draxis

<PAGE>
                                   - 5 -

Dan Brazier                                                     April 15, 1999

Pharmaceutica, Draxis and its Affiliates (together, the "Company"), whether
or not a trade secret within the meaning of the applicable law, which at the
time or times concerned is not generally known to Competitors (as defined
below) and which has been or is from time to time disclosed to or developed
by you as a result of your employment with Draxis. Confidential Information
includes, but is not limited to, the following information of the Company:

         (i)     new products;

         (ii)    marketing strategies and plans;

         (iii)   development strategies and plans;

         (iv)    manufacturing processes and technologies;

         (v)     research in progress and unpublished manuals or know how;

         (vi)    regulatory filings;

         (vii)   identity of and relationship with licensees, licensors or
                 suppliers of the Company;

         (viii)  finances, financial information, financial management
                 systems of the Company;

         (ix)    market research;

         (x)     market experience with products;

         (xi)    customer lists;

         (xii)   pricing;

         (xiii)  employee salaries, benefits and perquisites; and

         (xiv)   any other research, information or documents which you are
                 told or reasonably ought to know that the Company regards as
                 proprietary or confidential.

    (2) You agree that you shall hold all Confidential Information in the
strictest confidence, as a fiduciary. Without limiting such obligation, you
shall use Confidential Information only at times and places designated by
Draxis in furtherance of the business of the Company. You shall not, except
where Draxis otherwise provides its prior written consent, or where required
by law, directly or indirectly disclose to any Person any Confidential
Information, directly or indirectly sell, give, loan or otherwise transfer
any Confidential Information or copy thereof to any Person, publish, lecture
on or display any Confidential Information to any Person or use Confidential
Information for your own benefit or the benefit of any other Person.

    (3) Your obligations under this Section shall remain in effect with
respect to each item of Confidential Information until the date upon which
such Confidential Information has been publicly disclosed in a manner
properly authorized by Draxis or otherwise has become known to Competitors
without any breach of this Section by you.

    (4) For purposes of this Agreement, "Affiliate", "Affiliated" and
"Associate" have the meaning attributed to such terms in the CANADA BUSINESS
CORPORATIONS ACT, as amended from time to time, and any successor legislation
thereto.

    (5) For purposes of this Agreement, "Competitor" shall mean any Person
which engages or is preparing to engage, in whole or in part, in the design,
development, manufacture, marketing or sale of

<PAGE>
                                   - 6 -

Dan Brazier                                                     April 15, 1999

any products or services which compete directly with a product or service
which, during the two years immediately preceding the date of your departure
from Draxis for any reason, Draxis marketed or manufactured or at the time of
termination of this Agreement and your employment hereunder, is then
preparing to market.

    (6) For purpose of this Agreement, "Person" shall include individuals,
partnerships, associations, trusts, unincorporated organizations and
corporations and vice versa.

(b) NON-SOLICITATION AND NON-COMPETITION

    (1) You acknowledge that the pharmaceutical industry is a highly
competitive business. You acknowledge that as President of Draxis
Pharmaceutica, you will be a key executive of the Company, and that you will
acquire extensive background in and knowledge of Draxis Pharmaceutica's
business and the pharmaceutical industry in which it operates and as a member
of the Draxis Corporate Management group, you will acquire knowledge and
awareness of the business of Draxis and its Affiliates. You further
acknowledge that at time of signing this Agreement, Draxis Pharmaceutica
develops and markets its products on a North American basis. You recognize
that the information and knowledge you will gain is commercially valuable and
is deserving of protection by Draxis in order to permit Draxis and its
Affiliates to develop and maintain their competitive edge throughout North
America, and in the other jurisdictions in which it operates. Accordingly,
you agree that in the course of your employment, and thereafter for a period
of one year (or if such period is held to be excessive by a court of
competent jurisdiction then for a period of six months) you shall not,
without the prior written authorization of the President and Chief Executive
Officer of Draxis, or his designate, whether as principal, as agent, or as an
employee of, or in partnership, or association with any other Person, in any
manner whatsoever directly or indirectly:

         (i)   become employed by or associated or affiliated with any
               Competitor of the Company in North America in a function
               dealing with a product or service, which during the
               twelve-month period immediately prior to the termination of
               this Agreement and your employment hereunder, for any reason,
               competed directly with a product or service of the Company;

         (ii)  seek to employ or encourage others to employ or otherwise
               engage employees, agents or subcontractors of Draxis who are
               employed in Draxis Pharmaceutica, (who are employees, agents
               or subcontractors on the date this Agreement is terminated) or
               seek to in any way disrupt the relationship of those
               employees, agents or subcontractors with Draxis;

         (iii) obtain by any means whatsoever the business of any Person who
               at the time of the termination of this Agreement and your
               employment hereunder, was a customer of Draxis Pharmaceutica,
               if to obtain such business may result in a reduction of that
               Person's business with Draxis; or

         (iv)  approach any Person who at the time of the termination of this
               Agreement and your employment hereunder was a customer of
               Draxis Pharmaceutica with the intention of soliciting or
               enticing the business of that Person away from Draxis.

    For clarity, nothing prevents you from holding shares listed on a
Canadian, American or other stock exchange where your holdings do not exceed
5% of the outstanding shares so listed.

<PAGE>

                                     - 7 -

Dan Brazier                                                     April 15, 1999

(c)   REASONABLENESS

      You agree that the obligations set out in Sections 14(a) and (b)
together with your other obligations under this Agreement are reasonably
necessary for the protection of Draxis' proprietary and business interests
and you expressly agree that:

            (i)    the scope of each of the covenants set out in Sections
                   14(a) and (b) above in all respects, and in particular,
                   in respect of area, time and subject matter, are
                   necessary and reasonable because Draxis is marketing the
                   Draxis Pharmaceutica products on a North American basis;

            (ii)   given your general knowledge and experience, the
                   obligations contained in this Agreement will not preclude
                   you from becoming gainfully employed with other
                   employers who are not Competitors following termination
                   of this Agreement and your employment hereunder for any
                   reason.

(d)   BREACH OF AGREEMENT

      You also recognize that any breach of the terms and conditions of this
Agreement by you will result in material damage to Draxis, although it may be
difficult for Draxis to establish the monetary value of such damage.  You
therefore agree that Draxis shall be entitled to injunctive relief, in
addition to any other remedies available to it, in a court of appropriate
jurisdiction in the event of any breach or threatened breach by you of any of
the provisions of this Agreement.

15.   TERMINATION OF EMPLOYMENT

(a)   TERMINATION BY DRAXIS FOR CAUSE

      Draxis may terminate this Agreement and your employment hereunder at
any time for cause without notice and without payment of any kind of
compensation either by way of anticipated earnings or damages of any kind.
For all purposes in this Agreement, "cause" shall be defined as such of your
failure to perform, incapacity, or breach of duty that would be considered by
the Courts of Ontario to be just cause for dismissal in contracts of
employment of this nature.  The onus shall be upon Draxis to establish the
existence of such just cause and that there has been no condonation.  Draxis
agrees that "cause", particularly in the first year of your employment, shall
not include your failure to reach monetary goals or objectives not related to
your efforts, endeavors, and judgment.

(b)   TERMINATION BY DRAXIS WITHOUT CAUSE BUT WITH NOTICE

      Draxis may terminate this Agreement and your employment hereunder by
providing to you one year's actual notice of termination.  At its sole
discretion, Draxis may provide to you a shorter period of notice of
termination, in which case, the payments referred to in Section 15(c) shall
be applicable, but such payments as may be required by Sections 15(c)(1) and
(4) shall be reduced by the actual notice provided, so that the total notice
and compensation in lieu of notice provided to you shall be equivalent to one
year from the date you are advised of the termination.  Draxis understands,
and agrees, that during any such notice period you will be able to seek
suitable replacement employment.

<PAGE>

                                 - 8 -

Dan Brazier                                                     April 15, 1999

(c)   TERMINATION BY DRAXIS WITHOUT CAUSE AND WITHOUT NOTICE

      Draxis may terminate this Agreement and your employment hereunder, in
its sole discretion, without notice and without cause, effective immediately
upon the date you are advised of the termination.

      Except as outlined in Section 15(b), if your employment is terminated
without cause pursuant to this Section, or you are constructively dismissed,
Draxis shall:

      (1)   Pay to you a severance allowance equivalent to one year of your
            then Base Salary in a lump sum within two weeks following the date
            of such termination.

      (2)   Pay to you all outstanding vacation pay and any earned but unpaid
            salary up to the date of such termination within two weeks of the
            date of termination.

      (3)   Reimburse you for any business expenses incurred by you up to and
            including the date of such termination following provision by you
            of applicable receipts.

      (4)   Ensure that it has complied with all statutory obligations
            imposed by the EMPLOYMENT STANDARDS ACT.

      The payment referred to in paragraph 1, above, shall be guaranteed and
shall not be subject to set off or deduction as a result of your obtaining
alternate employment following such termination or otherwise mitigating any
damages arising from such termination.  Further, the payment referred to in
paragraph 1, above, is inclusive of all statutory payments, including
statutory termination and severance, which may be owed to you.

      The amounts paid to you pursuant to this paragraph shall be subject to
all required deductions.

      You authorize any outstanding amounts which you may owe to Draxis,
including, if this Agreement and your employment hereunder should be
terminated prior to August 1, 2000, the Signing and Retention Bonus in the
amount of $20,000 referred to in Section 8 to be deducted from the payment
referred to in Section 15(c)(1) above.

      TERMINATION PAYMENT FOLLOWING A CHANGE OF CONTROL

      (1)   In accordance with Section 15(d)(2) below, if there is a Change
of Control, as defined below, you shall be entitled to the following:

      A.    the amounts of any unpaid salary earned up to and including date
            of termination;

      B.    any unpaid vacation pay earned up to and including date of
            termination;

      C.    a lump sum amount, equal to two times your Base Salary in effect
            immediately prior to the date of the Change of Control; and

      D.    any statutory obligations imposed by the EMPLOYMENT STANDARDS
            ACT.

      The payment referred to in Section 15(d)(1)(C) above, shall be
guaranteed and shall not be subject to set off or deduction as a result of
your obtaining alternate employment following termination or otherwise
mitigating any damages arising from termination.  Further, notwithstanding
Section 15(d)(1)(D) above, the payment referred to in Section 15(d)(1)(C)
above, is inclusive of all statutory payments which may be owed to you
following termination.

      The amounts paid to you pursuant to this Section shall be subject to
all required deductions.

<PAGE>

                                    - 9 -

Dan Brazier                                                     April 15, 1999

      (2)   These payments outlined in Section 15(d)(1) shall become due and
payable if, and only if:

      A.    there has been a Change of Control; and

      B.    within 24 months following any Change of Control:

            (i)    your employment is terminated without cause by Draxis or by
                   any successor employer to Draxis, as the case may be; or
            (ii)   by its conduct as described below, Draxis or any successor
                   employer to Draxis, as the case may be, constructively
                   terminates your employment by:
                   -   relocating the position and/or location of your
                       principal office more than  20 kilometres from the
                       location of your office on the date immediately prior
                       to the Change of Control, without your consent; or
                   -   materially reducing your title, reporting
                       relationship, responsibilities or authority without
                       your consent; or
                   -   reducing the salary paid to you by the successor
                       employer or terminating or materially reducing the
                       value of your benefit programs, including, but not
                       limited to, life insurance benefits, accidental death
                       and dismemberment benefits, long term disability
                       benefits, extended health coverage, dental benefit,
                       which are referred to in Section 3 of this Agreement;
                       and

      C.    you elect in writing to receive the payments outlined in Section
            15(d)(1).

      (3)   For purposes of this agreement "Change in Control" means a
transaction or series of transactions whereby directly or indirectly;

            A.     any Person or combination of Persons acting jointly and in
                   concert (other than you or a corporation controlled
                   directly or indirectly by you) acquires a sufficient number
                   of securities of Draxis to materially affect the control of
                   Draxis as defined below.  For the purposes of this
                   Agreement, a Person or combination of Persons acting
                   jointly and in concert, holding shares or other securities
                   in excess of the number which, directly or following the
                   conversion or exercise thereof, would entitle the holders
                   thereof to cast 20% or more of the votes attached to all
                   shares of Draxis which may be cast to elect directors of
                   Draxis, shall be deemed to affect materially the control
                   of Draxis, in which case the Change in Control shall be
                   deemed to occur on the date that is the later of the date
                   that the security representing one more than that required
                   to cast 20% of the votes attached to all shares of Draxis
                   which may be cast to elect directors of Draxis is acquired
                   or the date on which the persons acting jointly and in
                   concert agree to so act;

            B.     Draxis shall consolidate or merge with or into, amalgamate
                   with, or enter into a statutory arrangement or business
                   combination with, any other Person (other than a
                   corporation controlled directly or indirectly by you) and,
                   in connection therewith, all or part of the outstanding
                   shares of Draxis which have voting rights attached thereto
                   shall be changed in any way, reclassified or converted into,
                   exchanged or otherwise acquired for shares or other
                   securities of Draxis or any other Person or for cash or any
                   other property and control of Draxis is thereby materially
                   affected, as defined above, in which case the Change in
                   Control shall

<PAGE>

                                      -10-

Dan Brazier                                                     April 15, 1999

              be deemed to occur on the date of closing of the consolidation,
              merger, amalgamation, statutory arrangement or business
              combination, as the case may be;

          C.  Draxis shall sell or otherwise transfer, including by way of
              the grant of a leasehold interest (or one or more subsidiaries of
              Draxis shall sell or otherwise transfer, including without
              limitation by way of the grant of a leasehold interest) property
              or assets aggregating more than 50% of the consolidated assets
              (measured by either book value or fair market value based on the
              most recent audited financial statements) of Draxis and its
              subsidiaries as at the end of the most recently completed
              financial year to any other Person or Persons, in which case the
              Change in Control shall be deemed to occur on the date of
              transfer of the assets representing one dollar more than 50% of
              the consolidated assets; or

          D.  the sale, transfer or any manner of disposition of 50% or more
              of the assets of, or 50% or more of Draxis' interest in, Draxis
              Pharmaceutica to an arm's length Person.

          other than a transaction or series of transactions which involves a
          sale of securities or assets of Draxis with which you are involved
          as a purchaser in any manner, whether directly or indirectly, and
          whether by way of participation in a corporation or partnership
          that is a purchaser or by provision of debt, equity or purchase
          leaseback financing (but excluding where your sole involvement
          with such a purchase is the ownership of an equity interest of less
          than 5% of the acquirer where the acquirer is a public company) and
          you and persons acting jointly and in concert with you hold
          securities of the acquirer which, directly, or following the
          conversion or exercise thereof, would entitle the holders thereof
          to cast 5% or more of the votes attached to all shares or other
          interests of the acquirer which may be cast to elect directors or
          the management of the acquirer.

Draxis shall use its reasonable best efforts to require any successor
(whether direct or indirect) to all or substantially all of its (or Draxis
Pharmaceutica's) shares and/or assets to expressly agree in writing to assume
and to perform this Agreement in the same manner that Draxis would have been
required to perform it if no such succession had occurred. If Draxis fails to
obtain any such successor's express written agreement prior to the effective
date of such succession, such failure shall be deemed to be a termination of
your employment by Draxis and such termination shall be deemed to have
occurred on the date immediately prior to the Change of Control date. In such
event, at the discretion of Draxis, Section 15(b) or (c) will not be
applicable, and Draxis shall pay to you those amounts outlined in section
15(d)(1) above and section 15(h) shall be applicable.

     (4) For greater certainty, notwithstanding the occurrence of an event
described in Section 15(d)(2)(c) hereof, this Section 15(d) shall not be
applicable in the event that you are offered a comparable position on
comparable terms (including the continuation of a Change of Control
provision) within Draxis or its Affiliates.

<PAGE>

                                      -11-

Dan Brazier                                                     April 15, 1999

(e)  TERMINATION BY DRAXIS WITHOUT CAUSE UPON DISABILITY

     If, as a result of incapacity due to physical or mental illness, you are
unable to render services of substantially the kind and nature, and
substantially to the extent required to be rendered in accordance with this
Agreement, and if such incapacity is expected to continue for a period of at
least six consecutive months from the date such incapacity commenced
("Absence Date") this contract may be deemed to be frustrated. Your
employment hereunder shall cease to be effective on the tenth day after
written notice of cessation to you, provided that prior to such cessation
Draxis has been furnished with the written certification of a qualified
medical doctor designated by Draxis and you jointly which states that you are
and are expected to continue to be for at least six consecutive months from
the Absence Date, unable to render such services by reason of such incapacity
and the date upon which such incapacity commenced. If Draxis and you are
unable to agree on the designation of a qualified medical doctor to make such
determination, then each party shall designate a medical doctor who,
together, shall agree upon a third qualified medical doctor to make such
determination. The decision of the third medical doctor shall be binding on
Draxis and you. You consent to submit to such examination as may be required
by any such medical doctor or doctors.

     If your employment ceases pursuant to this Section, you shall be
entitled to receive a total amount equivalent to one year then
Base Salary, commencing the date upon which the notice of cessation
is delivered and payable in 24 regular payments on the regular Draxis pay
days. If you are in receipt of disability benefits payable pursuant to the
benefit plans described above, then each semi-monthly payment payable by
Draxis shall be reduced by an amount equivalent to the disability benefits
payment received during that pay period.

     Further, notwithstanding Section 8, should your employment contract be
frustrated on or prior to August 1, 2000 in accordance with this Section,
Draxis will waive the payment of $20,000 referred to in Section 8.

     These payments shall be guaranteed and not subject to set off or
deduction as a result of your obtaining alternate employment following the
cessation of your employment or otherwise mitigating any damages arising from
such cessation. Further, these payments are inclusive of all statutory
payments which may be owed to you.

(f)  DEATH

     In the event that you should die during the term of this Agreement, your
employment shall automatically terminate. All Base Salary, vacation pay and
any bonus payments earned to date of death but unpaid will be paid to your
estate. In addition, if applicable, repayment of the $20,000 referred to in
Section 8 shall be waived, however, except as outlined in Section 15(h)
below, no other payment of any compensation either by way of anticipated
earnings or damages of any kind shall be paid.

(g)  RESIGNATION AND RETIREMENT

     You shall provide Draxis with two months' notice, in writing, of your
resignation or your retirement from Draxis.
<PAGE>

                                      -12-

Dan Brazier                                                     April 15, 1999

(h)  NO FURTHER NOTICE OR COMPENSATION

     For further clarity, in the event of termination of this Agreement and
your employment hereunder for any reason, the terms provided in the event of
termination under the Draxis Stock Option Plan, Stock Ownership Plan, and
Employee Participation Share Purchase Plan shall apply effective the date
upon which your termination actually occurs.

16.  FAIR AND REASONABLE

     The parties confirm that the notice requirements and pay in lieu of
notice provisions set out above in Section 15 are fair and reasonable and
that no further notice or payments of any kind are owed or required. The
parties agree that upon any termination of this Agreement by Draxis or upon
any termination of this Agreement by you, that you shall have no action,
cause of action, claim or demand, either statutory or at common law, against
Draxis, any of its Affiliates or their respective officers, directors,
employees or agents as a consequence of such termination.

17.  RETURN OF PROPERTY

     In the event your employment with Draxis is terminated for any reason,
including resignation or retirement, you will immediately return all Draxis
property in your possession or under your control.

18.  PROVISIONS OPERATING FOLLOWING TERMINATION

     Notwithstanding any termination of your employment with or without
cause, Sections 14, 15, 16 and 17 and any provision of this Agreement
necessary to give it efficacy shall continue in full force and effect
following such termination.

19.  ACKNOWLEDGEMENT

     You acknowledge that Draxis shall not, for any purpose, including in the
event of a subsequent termination, be required to recognize or take into
account any prior service with Allergan Inc.

20.  SEVERABILITY

     If any provision of this Agreement is determined to be invalid or
unenforceable in whole or in part, such invalidity or unenforceability shall
attach only to such provision or part thereof and the remaining part of such
provision and all other provisions hereof shall continue in full force and
effect.
<PAGE>

                                      -13-

Dan Brazier                                                     April 15, 1999

21.  NOTICE

     Any notice to be given in connection with this Agreement shall be given
in writing and may be given by personal delivery or by registered mail
addressed to the recipient as follows:

To:  Dan Brazier
     316 Lori Avenue
     Stouffville, Ontario
     L4A 6C2

To:  Draxis Health Inc.
     6870 Goreway Drive
     Mississauga, Ontario
     L4V 1P1
     ATTENTION: PRESIDENT AND CHIEF EXECUTIVE OFFICER

or such other address or individual as may be designated by notice by either
party to the other. Any notice given by personal delivery or by fax shall be
deemed to have been given on the day of actual delivery and, if made or given
by registered mail on the third day, other than a Saturday, Sunday or a
statutory holiday in Ontario, following the deposit thereof in the mail.

22.  GOVERNING LAW

     This Agreement shall be governed by and construed in accordance with the
law of the Province of Ontario.

23.  BENEFIT OF AGREEMENT

     This Agreement shall enure to the benefit of and be binding upon your
heirs, executors, administrators and legal personal representatives and the
successors and assigns of Draxis respectively.

24.  ENTIRE AGREEMENT

     This Agreement and the Draxis Code of Ethics constitutes the entire
agreement between the parties with respect to your terms and conditions of
employment and cancels and supersedes any prior understandings and agreements
between the parties to this Agreement. There are no representations,
warranties, forms, conditions, undertakings or collateral agreements
expressed, implied or statutory between the parties other than as expressly
set forth in this Agreement and the Draxis Code of Ethics. You waive any
right to assert a claim in tort based on any pre-contractual representations,
negligent or otherwise, made by Draxis.

<PAGE>

                                      -14-

Dan Brazier                                                     April 15, 1999

     To acknowledge that the terms of employment as expressed in this
Employment Agreement are acceptable to you, please execute the enclosed copy
of this letter as indicated below and return it to me at your earliest
opportunity.

                                 Yours truly,

                                 DRAXIS HEALTH INC.

                           Per:  /s/ Martin Barkin
                                 Martin Barkin, MD, FRCSC
                                 President and Chief Executive Officer

                                        *****

     I accept the above-noted terms of employment with Draxis Health Inc. as
the President of Draxis Pharmaceutica and in consideration of my continued
employment with Draxis Health Inc. and the payment of $5.00, the sufficiency
and receipt of which is acknowledged, I agree to comply with and be bound by
the terms of employment outlined in this Agreement.

Dated at Mississauga, as of the 20 day of April, 1999.

/s/ Debbie Carr Brazier                       /s/ Dan Brazier
-----------------------------------       --------------------------------------
Witness                                   Dan Brazier

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]